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INTRODUCTION 
 Cardiovascular disease is an epidemic of modern society. 
Myocardial infarction is a major cause of morbidity and mortality in the 
world. Despite the impressive strides in diagnosis and management over 
the past four decades, acute myocardial infarction continues to be a major 
public health problem in industrialized world and is becoming an 
increasingly important problem in developing countries. In United States, 
13 million individuals have ischemic heart disease,>6 million have angina 
pectoris,>7 million have persistent myocardial infarction. Because acute 
myocardial infarction may strike an individual during productive years, it 
can have profoundly deleterious psychosocial and economic 
ramifications. 
 After rupture of an atherosclerotic plaque in a coronary artery, 
there is platelet adhesion, activation and aggregation leading to the  
formation of a thrombus and ultimately culminating in acute myocardial 
infarction. So the more reactive the platelet are, higher the chances for 
myocardial infarction. 
 Assiri et al (2011) stated that platelet parameters mainly MPV and 
PDW are inexpensive lab tests which we detected to be significantly 
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raised in patient suffered from acute coronary syndrome compared with 
controls. 
 
Jasmine Jasani et al (2014) stated that acute coronary syndrome 
had higher platelet volume indices and lower platelet counts compared 
with those with stable angina and normal population. Measurements of 
platelet volume indices and platelet count benefit in detecting patients at 
higher risk for coronary events. 
 
S.C.Costa et al(2015) states that platelet indices as additional and 
complementary marker as thrombotic risk in acute coronary syndrome. 
Correlates macro platelets with higher thrombotic potential. 
 
So in this observational study, associations between platelet counts, mean 
Platelet volume and platelet distribution width as thrombotic risk in acute 
coronary syndrome were investigated in tertiary care hospital patient. 
 
AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
 
• To study the effect of platelet count and their indices-mean platelet 
volume and platelet distribution width and their prognostic 
significance in acute coronary syndrome. 
 
• To assess outcome of coronary heart disease patient. 
 
• To analyse the patient’s treatment pattern and follow-up 
arrangement. 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 The role of platelet in acute coronary syndrome has been 
appreciated for several decades. But the last 10-15 years have seen 
dramatic increase in understanding, development, clinical evaluation and 
therapeutic application of platelet inhibitor therapy.   
 Platelet released from megakaryocytes in the bone marrow play an 
essential role in haemostasis, thrombosis and coagulation of blood. These 
tiny cells previously described as” sponges” are known to engage in a 
complex repertoire of biochemical and molecular activities designed to 
prevent haemorrhage. (Adelson et ai,1961)1 
 Platelet indices indicates differentiation dysfunction, 
hyperactivation, aggregation or adhesion express disease pathogenesis 
(Maitree Bhattacharya et al, 2013)2 
 Platelets have major role in the pathogenesis of acute coronary 
syndrome, where plaque rupture is followed by platelet activation and 
thrombus formation leading to coronary artery occlusion.3,4,5. 
 Anti platelet agents have a cardinal role in management of patients 
with ACS by interrupt the pathologic cascade of thrombosis. Therefore, 
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acetylsalicylic acid, thenopyridine and glycoprotein 2b/3a inhibitors are 
platelet inhibitors used in the treatment of ACS patients.6 
HISTORICAL ASPECTS 
 Historically, platelets were referred to as cellular dust.7 The 
classification of platelet as blood corpuscles described by Bizzozero 
(1882).The importance of platelet to form haemostatic plug was reported 
by Eberth and scimmelbusch (1888).Another milestone in platelet 
involved in thrombogenesis identified by Aschoff(1925). 
PLATELET STRUCTURAL AND FUNCTIONAL ANATOMY 
LIGHT MICROSCOPY 
 On Wright-Giemsa stained blood smears, platelets appear as small 
anucleate, ovoid or round cells, with a pale greyish blue cytoplasm that 
contains homogeneously distributed purple –red granules. 
DIMENSIONS  
 The volumes of circulating platelets from a single individual are 
heterogeneous and exhibit a lognormal size distribution; and the platelet 
volume in a single individual (mean platelet volume, MPV) varies from 7 
to 9 femtolitres.(paulus,1975 et al8,Martin et al 19829;Stenberg and Lenin 
198910; corash, 1977)11. 
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ELECTRON MICROSCOPY AND SUBCELLULAR 
ORGANELLES 
                By scanning electron microscopy, circulating platelet appear as 
flat discs, with smooth contours and rare spiny filopodia. Scanning 
electron microscopy also reveals random openings of a channel system, 
the surface connected cannalicular system,which invaginates throughout 
the platelet and is conduit by which granule contents exocytose after 
stimulation. Although the platelet is anucleate,transmission electron 
microscopy reveals a cytoplasm packed with a number of different 
organelles essential to the maintenance of normal haemostasis. 
GLYCOCALYX 
      STRUCTURE: A glycocalyx 15 to 20 nm thick, is visualised by 
transmission electron microscopy and contains glycoprotein, glycolipids, 
mucopolysaccharides, and adsorbed plasma proteins. 
     FUNCTION:  The glycocalyx has a net negative surface charge due 
to sialic acid residues on the proteins and lipids; the charge is thought to 
minimize attachment of circulating platelet to each other (coller ,1984)12. 
This structure is rich in carbohydrate moieties of membrane –associated 
glycoproteins, which serve as receptors to mediate transfer of signals by 
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stimulatory agents .The glycocalyx interacts with platelet activators to 
facilitate platelet adhesion and aggregation. 
PLASMA MEMBRANE 
STRUCTURE:  
 The platelet plasma membrane is typical trilaminar membrane with 
glycoproteins, glycolipids, and cholesterol embedded in a phospholipids 
bilayer. 
FUNCTION:  
 The plasma membrane contains sodium and calcium ATPase 
pumps, which are important for maintaining ionic homeostasis. It has a 
specialized role in providing a surface for the acceleration of blood 
coagulation, in that specific platelet coagulant protein, platelet factor 3, 
resides in this lipoprotein –rich unit membrane 
SURFACE –CONNECTED CANALICULAR SYSTEM 
STRUCTURE:  
 The surface –connected canalicular system, also called the open 
canalicular system, weaves throughout the cell cytoplasm in a tortuous 
fashion. 
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FUNCTION:  
 The functions of the surface connected canalicular system are to 
provide a route entry and egress for molecules, an internal reservoir of 
membrane to facilitate platelet spreading and filopodia formation after 
adhesion and storage reservoir for membrane glycoprotein’s that increase 
on the platelet surface after activation. 
DENSE TUBULAR SYSTEM 
STRUCTURE:  
 Unlike the surface –connected canalicular system, the dense 
tubular system is a closed –channel system consisting of narrow, 
membrane limited tubules, approximately 400 to 600 A in diameter. It is  
infact, residual smooth endoplasmic reticulum from megakaryocytic. 
FUNCTION:  
 This channel system is involved in the regulation of intracellular 
calcium transport because it has been reported to selectively bind, 
sequester, and release divalent cations after activation. The dense tubular 
system is also the site of prostaglandin synthesis in platelets. 
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CYTOSKELETON: 
General structure:  
 The platelet cytoskeleton contains 30 to 50 % of total platelet 
protein and is made up of three major structural components: an actin 
microfilament network present throughout the cytoplasm, a micro tubule 
coil localized at the platelet periphery and a membrane skeleton 
comprising a network of short actin filaments that underlies the inner 
surface of the plasma membrane. Although they are distinct structures, 
interconnections between these elements are present. 
STRUCTURE AND FUNCTION OF SPECIFIC CYTOSKELETAL 
ELEMENTS 
Actin Microfilaments:  
 Twenty to thirty percent of total platelet protein is made up of actin 
(pollard, 1990).Actin exist in two forms ,G-actin (actin monomers) and  
F-actin (polymerized actin). In the unstimulated platelet,30-40% of actin 
is polymerized into filaments; the balance of actin monomers are 
prevented from polymerizing by protein such as profiling or thymosin B4 
that sequester nonnumeric actin, or by proteins that cap filaments in the 
intact cell, such as gelsolin. 
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           Upon platelet activation, the proportion of filamentous actin 
rapidly increases to 60-70%.Actin monomers polymerize into filaments at 
platelet peripheries and bundles of new filaments form to fill developing 
filopodia. 
MICROTUBULES:  
 A circumferential microtubule band that supports the discoid form 
of the platelet is made up of two nonidentical subunit protein such as 
alpha and beta tubulin associated with microtubule associated protein 
(MAP s).The 25nm diameter microtubule coil lies adjacent to, but does 
not touch, plasma membrane. 
            Microtubule is present primarily in their polymerized form in 
unstimulated platelets. Platelet activation results in microtubule 
disassembly, then reassembly; such alterations in marginal microtubule 
bundle result in platelet shape changes. 
Membrane skeleton:  
 The short actin filaments of the membrane skeleton, which underlie 
the inner surface of the plasma membrane, together with the microtubule 
coil, are thought to help stabilize the platelet discoid shape. 
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      Two major platelet membrane glycoprotein, GP IIb-IIIa and GP-IX 
are associated with the membrane skeleton. 
GRANULES  
 Platelet contain four distinct population of granules 
           1. Alpha 
  2. Dense bodies 
                   3. Lyosomes 
                   4. Microperoxisomes. 
 After platelet stimulation by agonist, granules fuse with channels of 
the surface –connected canalicular system and extrude their contents 
(white, 1974).Internal contraction is required for this extrusion and 
ultimate changes into the surrounding medium. 
 α  - Granules: 
          Structure: α Granules are the predominant granule type in the 
platelet. The α granule has been subdivided morphologically into three 
distinct zones by electron microscopy: 
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            1. Electron dense nucleoid that occupies the bulk of the granule 
            2. Peripheral zone of lower electron density that lies adjacent to 
the granule membrane  
             3. There are 1 to 6 tubular structures that reside in the electron 
lucent peripheral zone. 
 Content: B- thromboglobulin and platelet factor 4 have been 
localized to the dense nucleoid.Von willebrand factor is present in the 
tubular structures of the granule peripheral zone .Thrombospondin,and 
fibrinogen are present in the granular matrix. Other proteins present in α 
Granules include albumin, immunoglobin G (Ig G), fibronectin, 
platelet derived growth factor ,GP IIb ,IIIa ,Beta amyloid protein 
precursor, factor V, multimerin, factor V/Va binding protein, 
transforming growth factor β1 and a plasminogen activator similar to 
tissue plasminogen activator. 
                Proteins present on the α –granule membrane include P –
selectin, GPIIb / IIIa, granule membrane protein-33 (GMP-33), CD9, 
platelet –endothelial adhesion molecule 1 (PECAM-1) and osteonectin.  
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Dense Bodies: 
         Structure: Ultrastructurally, dense granules have a bull’s eye 
appearance .They are the most electron -dense organelles in platelets. 
        Contents: The principal constituents of dense granules are a non 
metabolic pool of adenine nucleotides (adenosine triphosphate and 
diphosphate, ATP and ADP), PPi, calcium and magnesium and serotonin 
(5-hydroxy trytamine). In addition, dense bodies contain guanosine 
triphophate and diphosphate (GTP and GDP).The dense granule 
membrane contains P-selectin and granulophysin. 
Lysosomes: 
 Structure: Liposome’s are small vesicles of approximately 175 to 
200 nm.  
 Content: Lysosomes are the only platelet granules that contain 
acid hydrolases. platelet lysosomes contain a large variety of enzymes, 
including β hexosaminidase and β glycerophosphatase. Lysosomal 
membrane glycoprotein (LIMP-CD63) and lysosomal associated 
membrane proteins 1 and 2 (LAMP-1 and LAMP-2) become expressed 
on the plasma membrane activation. 
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Microperoxisomes: 
          Stucture: Microperoxisomes are small (90nm) granules that are 
relatively few in number in platelets and can be demonstrated only 
cytochemically. 
         Content: They are reactive with alkaline diaminobenzidine 
medium. The enzyme responsible for the cytochemical peroxidise activity 
in microperoxisomes is catalase. 
 Coated vesicles: 
           Structure: coated vesicles are 70 to 90 organelles 
            Content: The polyhedral coat on the surface of these vesicles is 
composed of clathrin .Coated pits and vesicles transfer plasma 
components to platelet granule (Behnke, 1989)13 
Mitochondria: 
          Structure: Mitochondria in platelet are similar, with the 
exception of smaller size to those in other cell types. There are 
approximately seven per human platelet. 
           Content: Mitochondria are the site of activity for all components 
of the respiratory chain and all almost all enzymes in the citric acid cycle. 
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Glycogen: 
              Platelet contains small particles of glycogen or masses of closely 
associated glycogen particles; these play a essential role in platelet 
metabolism.               
PLATELET STRUCTURE 
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PLATELET PHYSIOLOGY 
Platelet lipid and proteins: 
Membrane lipids: 
Phospholipids contributes about 80% of total platelet lipid, 
although smaller amounts of neutral lipids and glycolipids are also 
present. The five major phospholipids identified in human platelets are 
1. phosphotidylcholine 
2. phosphatidylethanolamine 
3. spingomyelin 
4. phosphatidylserine 
5. phosphatidylinositol 
Almost all platelet fatty acids are esterified in phospholipids, 
leaving only trace amounts of free fatty acids. Arachidonic acid, the 
precursor of prostaglandins and thromboxanes, is enriched in these  
phospholipids and the metabolism of arachidonic acid is critical  for 
normal platelet function (Marcus,1976).14 
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Neutral lipids make up approximately 28% of total platelet lipids, 
the predominant neutral lipid being cholesterol. 
Membrane Glycoproteins: 
Platelet membrane glycoprotein’s function mediates a wide number 
of adhesive cellular interactions. These glycoprotein’s function as 
receptors that can receive signals from outside the platelet, facilitating 
cell-cell interactions; binding of specific ligands to these receptors results 
in distinct platelet responses to the external environment. 
Glycoprotein IIb/IIIa :  
 Glycoprotein IIb-IIIa is the principal receptor on the platelet 
plasma membrane (Phillips et al,1988).15It is a member of the integrin 
family of proteins. A ca2+ dependent conformational change in GP IIa –
IIIb after platelet agonist induced stimulation facilitates strong binding to 
fibrinogen and vWF resulting in cross linking of GP IIb-IIIa molecules on 
adjacent platelets and platelet aggregation. 
Glycoprotein Ib-IX:  
 Glycoprotein Ib mediates the interaction of platelet with vWF. 
GPIb also functions as binding site for thrombin. GPIb is present on 
platelet surface in a 1:1 ratio with GP IX. 
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Other membrane Glycoprotein’s:   
 Membrane glycoprotein GPI a-IIa,GPIc-IIa,mediate platelet 
adhesion to collagen, fibronectin, laminin and vitronectin.GP V forms a 
non covalent complex with GP IB-IX in the platelet membrane. PECAM 
-1 binds to heparin like molecules. GPIV is a receptor for 
thrombospondin.GP IV is also reported to bind collagen. 
Other platelet proteins: 
1. platelet factor 4 
2.β thromboglobulin 
3. thrombospondin 
4. platelet derived growth factor 
5. fibronectin 
Platelet Factor 4:  
 platelet factor 4 binds with heparin neutralizes its anticoagulant 
activity also inhibits endothelial cell proliferation, migration, and 
angiogenesis, potentiate platelet aggregation. 
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PLATELET BIOCHEMISTRY: 
 The platelet synthesize minimal protein because of less ability and 
also it contains low level of RNA and anucleate.As per its dry weight, 
platelet constitutes  
 - Carbohydrate -8% 
 - Protein -60% 
          - Lipid-15% 
  
20 
 
Minerals      - Magnesium 
  - calcium 
                    - potassium 
  - zinc 
Vitamin-B12,folic acid, ascorbic acid. 
PLATELET ENERGY METABOLISM: 
            Platelet has the energy metabolism almost similar to that of 
skeletal muscle. Both utilize glycolysis and synthesis and use excess 
amount of glycogen in both, the major mediator of intracellular energy 
use is an actomyosin-like adenosine triphsphatase. the platelet like that of 
muscle ,is metabolically active and expend excess energy rapidly during 
aggregation, the release, and clot retraction. 
           The major energy source for the platelet is glucose, which is 
rapidly taken up from the plasma. 
             Platelet energy metabolism is derived from glucose and to lesser 
extend from metabolism of fatty acid. Energy driven equal amount from 
glycolysis and citric acid cycle. Platelet energy reserve is provided by 
metabolic pool of platelet nucleotides that is continuous turnover. 
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Nucleotide metabolism: 
              Adenine nucleotides constitute 90% of free platelet nucleotides 
and are divided into two different pools. The metabolic or cytoplasmic 
pool constitutes 40 % of total adenine nucleotides. It is utilised for 
maintenance of various energy consuming cell functions and utilized 
during platelet release. 
Arachidonate Metabolism: 
             Arachidonic acid is released from platelet membrane 
phospholipids after stimulation by enzymatic action of phospholipids A2 
or phospholipase C and diglyceride lipase. After release, arachidonic acid 
can be acted by either lipoxygenase,results in production of peroxy and 
hydroxyl fatty acids or by cyclooxygenase ,which results in production of 
thromboxanes and prostaglandins. 
Platelet “coagulation ’’ Factors; 
 Numerous platelet protein interact with plasma coagulation protein 
although the mechanism by which platelet membrane component become 
reorganized and capable of functioning as a catalytic surface for plasma 
protein are not known. 
22 
 
 Plasma coagulation factors which are associated with platelets, 
including von Will brand factor, coagulation inhibitors, and factor XIII. 
 Numerous substance associated with or derived from platelet have 
been named as platelet factors 1 to 10 as Arabic numerals .The most 
important of these are PF4 and PF3. 
Platelet Factor 3 
 PF 3 is needed in two process in blood coagulation system, which 
are interaction between factors IXa and VIIIa ,which results in activation 
a factor X, as well as interaction between Xa and factor Va which leads to 
formation of prothrombinase. These coagulation reaction are greatly 
accentuated on platelet surface. 
PLATELET COUNT 
 The normal platelet count varies between 1,50,000 to 
3,50,000/mm³ 
ORIGIN OF PLATELET FROM MEGAKARYOCYTES 
 The megakaryocyte is a large progenitor cells in the bone marrow, 
which is the source of platelets. Platelet released from megakaryocyte 
through a series of fascinating cell biological events. During maturation, 
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they become polypoid and accumulate massive amounts of protein and 
membrane.      
 Then, in a cytoskeletal –driven process, they extend long branching 
process, named as proplatelets, into sinusoidal blood vessels were they 
release platelets. The time required for megakaryocyte to complete 
polyploidization, mature, and release platelets is 5 days in human,2-3 
days in rodents.(Ebbe and Stohlman ,1965; Odell and Jackson ,Odell et 
al.,1970) 
FASCINATING CELL BIOLOGICAL EVENTS: 
 1. Megakaryocyte development in adult bone marrow 
2. Endomitosis to create polypoid nucleus 
3. cytoplasmic maturation 
4. proplatelet formation and release 
5. preplatelet to proplatelet interconversion 
6. Platelet release 
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 They yield about 1000 and 8000 platelets having volume of 7-9 
femto litres each (Martin et al ,1982;Stenberg and Levin ,1989; Corash, 
1989) Megakaryocytes are suicidal micro organs whose mission is to 
proliferate and then fragment their cytoplasm on demand to maintain 
blood platelets at steady level 1,50,000 to 3,50,000/mm³ 
 Maintenance of platelet counts within this range represents a 
surplus of over 10 times that necessary to ensure routine haemostasis but 
providesa precautionary reserve for times of excess platelet loss or 
consumption. 
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THE INCREDIBLE JOURNEY: ORIGIN OF PLATELET 
FORMATION FROM MEGAKARYOCYTE 
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PLATELET LIFE SPAN, TURN OVER & REMOVAL: 
             Platelet life span, based on time needed to cleared from 
circulation, estimated approximately 8-12 days. The sites for platelet 
removal appear to be speen, liver and bone marrow. Degranulation and 
loss of density and platelet constituents has not been shown to decrease 
platelet life span indicating that number of haemostatic interactions may 
not be a key component. 
PLATELET ADHESION, ACTIVATION & AGGREGATION: 
               The antithrombotic properties of intact vascular endothelium 
include potent platelet inhibitors. These inhibitors include PGI2, NO 
&CO which are labile molecules that are released by endothelial cells and 
act locally as autacoids and ADPase, an ectonucleotidase of endothelial 
membranes that break down platelet activating ADP. 
ADHESION: 
           On vascular intimal injury, the antiplatelet properties of local 
endothelium diminished, while previously considered as cryptic, 
thrombogenic sub endothelial substance eg.collagen become exposed to 
flowing blood. Circulating platelet recognize vascular disruption site and 
undergo the adhesion process at the site of vascular injury. 
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           Platelet adhesion is mediated by von willebrand factor which is 
present in the extracellular matrix of sub endothelial vessel wall. The 
receptor of von willebrand factor on the platelet surface is localized in 
membrane glycoprotein (Gp) Ib,part of the platelet membrane Gp Ib/ IX-
V complex. Platelet adhesion is also facilitated by direct binding to sub 
endothelial collagen by means of specific platelet membrane collagen 
receptors. 
ACTIVATION:  
 Adherent platelets then become activated. The platelet activation 
process results from integrative action of several agonists that bind to 
their respective membrane receptors on adherent platelets and transmit 
platelet activating intracellular signals. These platelet stimuli results from 
various mediators 
1. Humeral mediators in plasma (epinephrine, thrombin) 
2. Mediators from activated cell (ADP, serotonin) 
3. Vessel wall extracellular matrix (collagen,von willebrand factor) 
 Activated platelet then undergo release reaction during which they 
secrete pre-packaged constituents of their cytoplasmic granules. 
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Dense granules release-ADP, ATP, serotonin 
α -granule release  
1. soluble adhesive protein-(fibrinogen, von willebrand factor,  
thrombospondin, fibronectin) 
          2. Growth factors-(PDGF, TGF α,TGF β) 
          3. procoagulants (platelet factor 4,Factor V) 
 Simultaneously, activated platelet synthesize denovo and release 
the potent platelet activator and vasoconstrictor thromboxane (TXA2) 
AGGREGATION: 
 The products of the platelet release reaction, including secreted 
granule constituents and (TX2) mediate aggregation. During platelet 
aggregation, additional platelets are recruited from circulation to the site 
of vascular injury leading to the formation of occlusive platelet thrombus. 
 At the lower shear level (eg.in venous circulation), the molecular 
glue that mediates aggregation is fibrinogen, which can be derived either 
from plasma or from α – granule releasate of activated platelets. At higher 
level shear (eg.in arteries) von willebrand factor can substitute for 
fibrinogen as the ligand of aggregation. 
           Fibrinogen or von willebrand factor binds to the sp
membrane receptor that are located in the GP IIb/IIIa complexand 
mediates aggregation and finally platelet plug is formed. The platelet plug 
is anchored and stabilized by the fibrin mesh that develops 
simultaneously as the product of coagul
29 
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PATHOGENESIS OF ACUTE MYOCARDIAL INFARCTION 
       Almost all myocardial infarction result from coronary 
atherosclerosis, generally with superimposed coronary thrombosis. 
During the natural evolution of atherosclerotic plaques, especially those 
that are lipid laden, an abrupt and catastrophic transition may occur 
characterized by plaque rupture .After plaque rupture there is exposure of 
substance that promote platelet activation and aggregation, thrombin 
generation and ultimately thrombus formation. The resultant thrombus 
that is formed interrupts blood flow and leads to an imbalance between 
oxygen supply and demand and if this imbalance is severe and persistent, 
to myocardial necrosis. 
PLATELET VOLUME AND CARDIOVASCULAR DISEASE 
 As the initial step in the pathogenesis of acute myocardial 
infarction is plaque erosion or rupture followed by platelet adhesion, 
activation & aggregation followed by thrombus formation, platelet with 
more activity will predispose to the occurrence of myocardial infarction. 
Mean platelet volume (MPV) correlates with platelet function and 
activation, whether measured as aggregation, thromboxane synthesis, β 
thromboglobulin release, procoagulant function or adhesion molecule 
expression. (Bath et al,1996).16 
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  Increased platelet reactivity as well as shortened bleeding time are 
associated with increased platelet volume (Milner & Martin, 1985; 
Trowbridge & Martin, 1987)17. large platelets are metabolically and 
enzymatically more active than small platelet as assessed by invitro 
aggregometry(Corash et al 1977)18 and they have higher thrombotic 
potential (karpatkin 1972)19.they also express higher levels of 
procoagulatory surface proteins such as P-selectin (Mathur et al , 2001)20 
and glycoprotein III a( pathansali et al,2001)21 
           Large platelets are denser; they produce more thromboxane A2 per 
unit volume of platelet cytoplasm and decrease bleeding time more than 
control platelets. Larger platelets aggregate more rapidly upon collagen 
challenge, release more serotonin & other granule contents and express 
more receptors per unit area (pizzuli et al, 1998)22. 
          Platelet morphology and physiology are determined during or even 
before fragmentation of their precursor cell,the megakaryocyte (Rabellino 
et at 1981)23.Although the mechanism is still unclear, megakaryocyte 
plody seems to correlate closely with platelet volume(Hoffman and Long 
1995)24.Although ploidy and platelet volume are independent variables, 
alteration in both parameters usually occur in tandem(Trowbridge and 
Martin ,1987). Certain cytokines such as Interleukin -3,thrombopoetin 
and in particular interleukin 6(IL-6) seem to have major influence on 
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megakaryocyte ploidy leading to the production of larger and more 
reactive platelets 9 (Debilli et al 1993;Brown et al 1997).Recently a 
frequent G/C polymorphism in the promoter region of IL-6 at nucleotide 
position (-174) has been shown to influence IL-6 serum levels (Fishman 
et al 1998). In individual carrying the common G allele, higher IL-6 
levels have been found compared with the levels in carriers of the C allele  
(Fishman et al 1998). 
       Large platelets are not necessarily young platelets (Martin et al, 
1983) and there is now no convincing evidence that platelets appreciably 
change volume or density as they circulate (Penington, 1976). 
          Various studies found an association between mean platelet volume 
and coronary artery disease or the occurrence of an acute myocardial 
infarction (Assiri et al, 2012)25 while others observed no effect 
(Halbmayer et al 1995) 
Platelet volume and prognosis following acute myocardial infarction: 
 Hendra et al (1988)26 observed that all patients with severe cardiac 
failure had larger platelet volumes than patients with mild or no 
failure.Osuna et al (1998)27 stated that increase in mean platelet volume 
on admission was an independent risk factor for cardiac failure. 
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          Increased MPV was found to be an independent risk factor for 
recurrent myocardial infarction by Martin et al (1982)28 
 Yilmaz et al(2004)29 observed that in patients with dilated 
cardiomyopathy and in sinus rhythm, an increased MPV was associated 
with an increased incidence of left ventricular thrombus. 
          D.de Gonzalo-Calvo et al (2013)30 states that platelet distribution 
width could be a predictor of 1 –year mortality in elderly population used 
as valuable tool for recognizing high risk individual so we can prevent by 
applying early stage  preventive strategies. 
           In contrast to the above observations, Cameron et al (1983)31 noted 
that the increase in MPV did not appear to provide any prognostic 
information after myocardial infarction. The value in patients who died 
was no different from that of the survivors. The MPV did not correlate 
with the more established factors determining prognosis after myocardial 
infarction such as size of the infarct. 
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AGE, SEX AND MPV 
 Funiak et al (1994)32 observed increased MPV in patients advanced 
age. In contrast Bancroft et al (2000)33 observed decreased MPV with 
advanced age. He observed no difference between genders. 
MPVANDSMOKING 
           Smokers were found to have an increased MPV (Tschope et al, 
198934; Kario et al ,1992)35. 
MPVANDOTHERDISEASES    
 An increased MPV was observed in diabetics compared with non 
diabetic by sharpe et al (1993)36 
          Although Osuna et al (1998) 37observed a higher MPV in those 
with systemic hypertension,Bathet al (1996)38 observed no such effect. 
 Ford et al (1998)39 observed that patients with hyperthyroidism and 
increased MPV. 
 Bansal et al (2002)40 stated that MPV was increased in patients 
with chronic obstructive pulmonary disease and this could possibly 
contribute to an increased incidence of pulmonary embolism in these 
patients. 
35 
 
 In chronic liver disease, MPV and platelet count are decreased 
(Jorgensen et al, 1984)41.  
MPV AND DRUGS 
 Aspirin  has no effect on MPV (pizulli et al,1998).Recently ,invitro 
data on the therapeutic effects on platelet volume of losartan,an 
angiotensin II receptor antagonist or Doxasosin ,an α 1adrenoceptor 
antagonist, have been reported (Jagroop and mikhailidis 2001)42.These 
observation have not been confirmed in vivo (jagroop and mikhailidis 
2000). 
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MATERIALS AND METHODS 
Setting   :  Dept of Medicine and Intensive coronary  
    care unit, Rajiv Gandhi  Govt, General                            
    Hospital Madras medical college,  
    Chennai. 
                                                                                                                       
Collaborating  
Department     : Dept of cardiology, Govt.Rajiv Gandhi                                                     
                                                 Hospital and Madras Medical college, 
     Chennai. 
 
Design of study  :  Observational prospective analytical  
     study 
  
Period of study  :  6 months 
 
Sample size   :  65 patients and 35 controls 
 
Ethical committee  
approval      :  The present project was approved by the  
     Ethical committee. 
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INCLUSION CRITERIA: 
 1. Age ranged from 18 to 80years. 
 2. Patient diagnosed as unstable angina, 
          STEMI-ST segment elevation myocardial   infarction 
  NON –STEMI-non-ST segment elevation myocardial infarction 
 
EXCLUSION CRITERIA 
1. Patients with active hemorrhage 
2. Patients with hematological disorders like leukemia, lymphoma 
and bone marrow disorders 
3. Patients who have been transfused blood or platelet prior to 
admission – 8 days back 
4. Patients who received chemotherapy / radiotherapy 
5. Previous stroke 
6. Blood pressure >180/110mmhg 
7. Patient less than 18 years of age 
8. Patient with non cardiac chest pain 
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CONTROLS: 
 Age and sex matched subjects who did not have angina pectoris, 
ECG evidence of coronary artery disease, history of previous coronary 
artery disease and who met the above exclusion criteria were kept as 
controls.  
CONSENT: 
 Informed consent was obtained from all those who participated in 
the study or their relatives. 
MATERIALS: 
 Thus a total of 65 cases who satisfied the inclusion and exclusion 
criteria stated above were taken up for subsequent study.35 age and sex 
matched subjects were kept as control 
Definitions used for the study: 
1. Acute myocardial infarction: 
 A patient was considered to have acute myocardial infarction if 
he/she gave a definite clinical history suggestive of acute myocardial 
infarction and ECG shows ST segment elevation. 
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 STEMI-ST segment elevation myocardial infarction >1mmin 
any two or more adjacent precordial or  limb leads with                    
elevated cardiac biomarkers 
 NSTEMI-Non ST Elevation myocardial infarction-ST 
segment depression or T wave inversion with elevated 
cardiac biomarkers. 
 Unstable angina-ST depression or T wave inversion without 
any elevation of cardiac biomarkers. 
2. Smoking: 
 A subject was considered to be a smoker if he /she gave a history 
of tobacco smoking within the past 20 years. Person who had quit 
smoking completely before 20 years were not considered as smokers. 
3. systemic hypertension; 
 A subject was considered to have systemic hypertension if he was 
already diagnosed to have systemic hypertension and was on anti 
hypertensive medication or if the systolic blood pressure during hospital 
stay was found to be more than or equal to 140mmHg and /or the 
diastolic blood pressure was more than  or equal to 90mmHg according to 
JNC VIII report. 
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4. Diabetes mellitus: 
 A subject was considered to have diabetes mellitus if he/she was 
already diagnosed to have diabetes mellitus or during hospital Stay was 
found to have a Fasting plasma glucose of  ≥ 126 mg/dl 
Or 
 2 hour postprandial plasma glucose ≥200mg/dl 
Or 
 Symptoms of diabetes mellitus plus random blood sugar 
≥200mg/dl. 
 5. Left ventricular dysfunction 
 Left ventricular dysfunction was divided to mild, moderate, severe   
According to ejection fraction in ECHO 
                   ≤29%             severe 
                    30-39             moderate 
                   40-49              mild 
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6. Short term outcome-outcome at the end of 7 days after acute  
 myocardial infarction was considered with respect to left 
ventricular dysfunction, left ventricular clot in ECHO, recurrence of 
angina, occurrence of arrhythmia, occurrence of death. 
Methods: 
              Selected socio-demographic, clinical and laboratory data were 
collected from the patients and controls and recorded in a proforma 
(enclosed in Appendix-Appendix I) 
I.socio –demographic data comprised of 
• Age 
• Sex 
• History of smoking  
• Family history of coronary artery disease 
II.Clinical Data 
• History  
• Clinical examination               
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III.Laboratory Data 
• Blood sugar 
• ECG 
• Echocardiogram 
• Platelet count 
• Mean platelet volume 
• Platelet Distribution Width 
 ECG- 12 lead multi channel ECG was taken in all the patients. 
ECHO-Tran thoracic ECHO was done using ALOKO PRO S  100 in all 
the cases.2 D ECHO, M-MODE ECHO was done to  analyse the regional 
wall motion abnormality, presence of clot and also to assess the left 
ventricular function. Colour Doppler evaluation was done to evaluate the 
presence of valvular regurgitation and also to assess the diastolic 
function.   
 For the above mentioned haematological parameters, 2ml of blood 
was withdrawn by venepuncture from the patients within 24 hours of 
admission to the hospital. The  venepuncture  site was properly cleaned 
and blood withdrawn  and collected in EDTA containing disposable tubes 
available  in the market. The sample was transported immediately to a 
quality controlled centre where the sample was analysed for platelet 
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volume. The instrument was started up. After start up,  a pipette appeared 
from the instrument. Blood sample was fed to the instrument by the 
principal worker. The pipette drew the necessary amount of blood. From 
that moment a waiting time  of 180 seconds appeared on the instrument. 
At the end of 180  seconds, a print out with the platelet count and mean 
platelet  volume and platelet distribution width  was ejected from the  
printer connected to the instrument. The instrument was repeatedly 
standardized for quality control. 
Conflict of interest: 
 There was no conflict of interest. 
Financial support: 
 Nil 
Limitations: 
1. Technical constraints and the cost factor of the investigation have 
led to limited number of cases. 
2. Since the lipid levels were found to be an independent of  mean 
platelet volume in earlier studies, it was neither   considered for the 
present study nor taken for analytical purposes. 
  
44 
 
STATISTICAL ANALYSIS: 
 Data were entered in Microsoft excel spread sheet and analysed 
utilizing the software-Epidemiological information Package 2002(Epi 
Info 2002)- developed  by the centre for disease control and prevention, 
Atlanta for World Health Organisation. Range, Median, Mean and 
Standard deviation and ‘p’ values were calculated using this package.  
 Chi –square test was done to find out the significance of 
relationship between the groups. Significance was considered if the ‘p’ 
value was below 0.05. 
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OBSERVATIONS AND RESULTS 
 The   total number of subjects included in the study was 100.   
Among the 100 subjects, 65 cases and 35 controls and their profile is 
furnished below    
AGE DISTRIBUTION :  
 The age of the cases ranged from 20-80 years and that of controls 
ranges from 28-75 years. The mean and standard deviation for the cases 
were 52.98±15.00 years and those for the controls were 49.03±10. 
36 years. There was no significant difference with respect to age among 
them. The distribution of cases and controls with respect to age is given 
below in the table -1 given below. 
TABLE -1 
1. Distribution of case and control with respect to age 
 
 
AGE_GROUP 
Total 20-40 41-60 61-80 ABOVE 80 
GROUP 
CASE 
MI 
Count 16 25 22 2 65 
% within 
GROUP 24.6% 38.5% 33.8% 3.1% 
100.0
% 
CONT
ROL 
Count 9 22 4 0 35 
% within 
GROUP 25.7% 62.9% 11.4% 0.0% 
100.0
% 
Total 
Count 25 47 26 2 100 
% within 
GROUP 25.0% 47.0% 26.0% 2.0% 
100.0
% 
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2. SEX DISTRIBUTION: 
     Among the 65 cases studied, there were 45 males and 20 females. 
Among the controls, there were 25 males and 10 females. The difference 
in the sex composition of the case and control was not statistically 
significant. The details are furnished in Table -2 depicted below. 
 
TABLE 2 
Distribution of case and control in relation to gender 
 
 
 
 
 
SEX 
Total 
Male Female 
GROUP 
CASE MI 
Count 45 20 65 
% within 
GROUP 
69.2% 30.8% 100.0% 
CONTROL 
Count 25 10 35 
% within 
GROUP 
71.4% 28.6% 100.0% 
Total 
Count 70 30 100 
% within 
GROUP 
70.0% 30.0% 100.0% 
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3.SMOKING: 
 Among the 65 cases 40 had the habit of smoking. Among the 35 
controls, 13 had the habit of smoking. There were no female smokers in 
either group. There was no statistical difference in the habit of smoking 
between cases and controls. The details are depicted in the table-3 given  
below. 
TABLE 3 
Distribution of case and control with respect to habit of smoking 
 
SMOKING Total 
Yes No  
GROUP 
CASE MI 
Count 40 25 65 
% within 
GROUP 75.5% 53.2% 100.0% 
CONTRO
L 
Count 13 22 35 
% within 
GROUP 24.5% 46.8% 100.0% 
Total 
Count 53 47 100 
% within 
GROUP 54.0% 46.0% 100.0% 
  Pearson Chi-Square =5.435,P=0.020 
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4.DIABETES MELLITUS: 
 Among the 65 cases, 29 had diabetes mellitus. Among the 35 
controls, 8 had diabetes mellitus. There was statistically significant 
difference among cases and controls with respect to diabetes mellitus. 
The details are given in the table-4 shown below. 
TABLE-4 
Distribution of case and control with respect to diabetes 
 
DIABETES Total 
Yes No 
GROUP 
CASE MI 
Count 29 36 65 
% within 
GROUP 78.4% 57.1% 100.0% 
CONTRO
L 
Count 8 27 35 
% within 
GROUP 21.6% 42.9% 100.0% 
Total 
Count 37 63 100 
% within 
GROUP 100.0% 100.0% 100.0% 
 Pearson Chi-Square =4.620 ,P=0.032 
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5.SYSTEMIC HYPERTENSION: 
 Among the 65 cases ,35 had  systemic hypertension. Among the 35 
controls, 19 had systemic hypertension. Systemic hypertension was 
present among cases and controls with statistically significant difference.  
 The details are provided in the table- 6 given below. 
TABLE -5 
Distribution of case and control with respect to hypertension 
 
 
HYPERTENSION Total 
Yes No 
GROUP 
CASE 
MI 
Count 35 30 65 
% within 
GROUP 76.1% 55.6% 100.0% 
CON
TROL 
Count 19 15 34 
% within 
GROUP 23.9% 44.4% 100.0% 
Total 
Count 47 52 99 
% within 
GROUP 100.0% 100.0% 100.0% 
   Pearson Chi-Square=4.603,P=0.032 
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 6.ASPIRIN INTAKE
Distribution o
 
Valid 
Yes 
No 
Total 
 
 
52%
55 
. 
TABLE 6 
f case with respect to aspirin intake
ON_ASPIRIN 
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
31 47.7 47.7 
34 52.3 52.3 
65 100.0 100.0 
 
48%
ON_ASPIRIN
 
Percent 
47.7 
100.0 
 
 
Yes 
No 
  Frequency
Valid 
1.00 
2.00 
Total 
 
 
 
60%
56 
STEMI 
 Percent Valid Percent 
26 40.0 40.0 
39 60.0 60.0 
65 100.0 100.0 
 
40%
STEMI
Cumulative 
Percent 
40.0 
100.0 
 
 
Yes 
No 
  Frequency
Valid 
1.00 
2.00 
Total 
 
 
 
72%
57 
NSTEMI 
 Percent Valid Percent 
18 27.7 27.7 
47 72.3 72.3 
65 100.0 100.0 
 
28%
NSTEMI
Cumulative 
Percent 
27.7 
100.0 
 
 
Yes 
No 
  Frequency
Valid 
1.00 
2.00 
Total 
 
 
 
69%
58 
UNSTABLE_ANGINA 
 Percent Valid Percent 
20 30.8 30.8 
45 69.2 69.2 
65 100.0 100.0 
 
31%
UNSTABLE_ANGINA
Cumulative 
Percent 
30.8 
100.0 
 
 
Yes 
No 
 7.PLATELET COUNT
 The mean platelet count of the cases was4.98±0.23lakhs/mm³
that of the controls was 1.29±0.42
significant). 
 GROUP 
PLATEL
ET_COU
NT 
CASE MI 
CONTROL 
t=1.962  p=0.05  significant
 
0.00
1.00
2.00
3.00
4.00
5.00
MEAN PLATELET_COUNT IN LAKHS 
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:   
 Lakhs/mm³ (p value 0.050 
TABLE 7 
platelet count in case and control 
Group Statistics 
N Mean Std. Deviation
65 495606.1538 1493656.28408
35 132028.5714 29341.28362
 
 
CASE MI CONTROL
4.96
1.32
 and 
statistically 
 Std. Error Mean 
 185265.26076 
 4959.58214 
 8. MEAN PLATELET VOLUME
 The MPV of the cases ranged from 8.4 to 12 femtolitres with a 
mean of 10.2 ± 1.1femtolitres
10.60 femtolitres with mean of 8.29±0.9 femtolitres.
between the two was statistically significant.(p value 0.001 significant).
 GROUP
MPV 
CASE MI
CONTRO
t=8.843**  p<0.001  significant
0.00
2.00
4.00
6.00
8.00
10.00
12.00
60 
: 
.The MPV of the controls ranged from 7 to 
 
TABLE -8 
MPV in case and control 
 N Mean Std. Deviation
 65 10.2662 1.13072
L 35 8.2914 .92906
 
CASE MI CONTROL
10.26
8.29
MEAN MPV
The difference 
 
 
Std. Error 
Mean 
 .14025 
 .15704 
 
 9.PLATELET DISTRIBUTI
 GROUP
PDW 
CASE MI
CONTROL
t=5.548**  p<0.001 significant
 
 
 
0.00
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10.00
12.00
14.00
61 
ON WIDTH  
TABLE-9 
PDW in case and control 
 N Mean Std. Deviation
 65 13.0646 2.23092
 35 10.7629 1.38438
 
 
CASE MI CONTROL
13.07
10.76
MEAN PDW
 
Std. Error 
Mean 
 .27671 
 .23400 
 10.RELATIONSHIP BETWEEN PLATELET COUNT AND 
ACUTE CORONARYSYNDROME
Platelet count in STEMI
  
 
    
STEMI 
PRESENT
ABSENT
NSTEMI 
PRESENT
ABSENT
UNSTABLE 
_ANGINA 
PRESENT
ABSENT
 
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
MEAN PLATELET  COUNT IN LAKHS FOR 
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TABLE -10 
, NSTEMI, Unstable angina
PLATELET_COUNT
Mean Maximum Minimum 
 887000 8800000 66000 
 234676.9 397000 80000 
 206222.2 343000 98000 
 606434 8800000 66000 
 264520 397000 80000 
 598311.1 8800000 66000 
PRESENT ABSENT
8.87
2.35
STEMI
 
 
Median Standard Deviation 
250000 2331358 
235000 83608.72 
201000 66571.11 
255000 1748443.9 
282000 89071.34 
222000 1790703 
 
  
 
 
0.00
2.00
4.00
6.00
8.00
MEAN PLATELET  COUNT IN LAKHS FOR 
0.00
1.00
2.00
3.00
4.00
5.00
6.00
MEAN PLATELET  COUNT IN LAKHS FOR 
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PRESENT ABSENT
2.06
6.06
NSTEMI
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 11.RELATIONSHIP BETWEEN MEAN PLATELET VOLUME 
AND ACUTE CORONARY SYNDROME 
MPV in STEMI,
  
  
STEMI 
PRESENT
ABSENT
NSTEMI 
PRESENT
ABSENT
UNSTABLE 
_ANGINA 
PRESENT
ABSENT
 
9.40
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9.80
10.00
10.20
10.40
10.60
10.80
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TABLE -11 
 NSTEMI, unstable angina
MPV 
Mean Maximum Minimum 
 10.79 13.8 8.2 
 9.92 11.7 8 
 10.02 11.7 8.4 
 10.36 13.8 8 
 9.75 11 8 
 10.5 13.8 8.2 
PRESENT ABSENT
10.79
9.92
MEAN MPV
 
Median Standard Deviation 
10.9 1.26 
9.9 0.89 
9.95 0.91 
10.3 1.2 
9.8 0.82 
10.4 1.18 
 
  
 
9.8
9.9
10
10.1
10.2
10.3
10.4
PRESENT
9.2
9.4
9.6
9.8
10
10.2
10.4
10.6
MEAN MPV IN UNSTABLE ANGINA
65 
ABSENT
10.02
10.36
MEAN MPV IN NSTEMI
PRESENT ABSENT
9.75
10.5
 
 
 12. PLATELET DISTRIBUTION WIDTH IN ACUTE CORONARY
SYNDROME 
PDW in STEMI,
 
 
STEMI 
PRESENT
ABSENT
NSTEMI 
PRESENT
ABSENT
UNSTABLE 
_ANGINA 
PRESENT
ABSENT
 
11
11.5
12
12.5
13
13.5
14
14.5
66 
TABLE-12 
 NSTEMI, unstable angina
 
PDW 
 
Mean Maximum Minimum 
 14.32 21.4 10.5 
 12.23 15.6 8.8 
 12.39 15.6 9.7 
 13.32 21.4 8.8 
 11.99 15 8.8 
 13.54 21.4 9.7 
PRESENT ABSENT
14.32
12.23
MEAN PDW IN STEMI
 
 
Median 
Standard 
Deviation 
14.15 2.51 
12.3 1.56 
12.45 1.43 
13.4 2.43 
11.95 1.66 
13.5 2.3 
 
  
 
9.8
9.9
10
10.1
10.2
10.3
10.4
9.2
9.4
9.6
9.8
10
10.2
10.4
10.6
MEAN MPV IN UNSTABLE ANGINA
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PRESENT ABSENT
10.02
10.36
MEAN MPV IN NSTEMI
PRESENT ABSENT
9.75
10.5
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TABLE -13 
Relation ship of  platelet count, MPV, PDW with ejection fraction 
Correlations 
 
PLATELET_
COUNT PDW MPV 
EJECTION_FRACTI
ON 
Pearson 
Correlation -.033 -.377
**
 -.238 
Sig. (2-tailed) .795 .002 .057 
N 65 65 65 
**. Correlation is significant at the 0.01 level (2-tailed). 
TABLE-14 
Relationship of platelet count, MPV, PDW with complication 
difference between two groups 
 
COM
PLIC
ATIO
N 
N Mean Std. Deviation 
Std. Error 
Mean 
t 
value 
P 
value 
PLATEL
ET_COU
NT 
1.00 12 950500.0000 
2472885.524
68 
713860.5616
8 1.172 0.246 
2.00 53 392611.3208 
1180550.959
65 
162161.1455
9 
PDW 1.00 12 15.4333 2.94906 .85132 4.695
** 
P<0.0
01 2.00 53 12.5283 1.64251 .22562 
MPV 1.00 12 11.3083 1.29507 .37385 3.911
** 
P<0.0
01 2.00 53 10.0302 .95466 .13113 
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PLATELET
_COUNT 
PDW MPV 
Kendall's 
tau_b 
COMPLICATI
ON 
Correlation 
Coefficient 
-.069 -.368** -.318** 
Sig. (2-tailed) .504 .000 .002 
N 65 65 65 
Sig. (2-tailed) .008 .000 . 
N 65 65 65 
Spearman's 
rho 
COMPLICATI
ON 
Correlation 
Coefficient 
-.083 -.442** -.381** 
Sig. (2-tailed) .508 .000 .002 
N 65 65 65 
Correlation is significant at the 0.05 level (2-tailed).  
Correlation is significant at the 0.01 level (2-tailed).    
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TABLE -15 
Relationship of platelet count, MPV, PDW with death difference 
between two groups  
Group Statistics   
 DEATH N Mean Std. Deviation Std. Error Mean 
t 
valu
e 
P 
value 
PLATELET
_COUNT 
1.00 4 214000.0000 111513.82575 55756.91287 0.38
7 
0.70
0 
2.00 61 514072.1311 1540612.79714 
197255.25
573 
PDW 
1.00 4 16.3000 1.83848 .91924 3.20
3* 0.02 2.00 61 12.8525 2.09671 .26846 
MPV 
1.00 4 11.5750 .37749 .18875 2.48
4* 
0.01
5 2.00 61 10.1803 1.11128 .14228 
 
Correlations 
 
PLATELE
T_COUNT PDW MPV 
 DEATH 
Correlation 
Coefficient .046 -.297
**
 -.269** 
Sig. (2-tailed) .652 .004 .010 
N 65 65 65 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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                                            TABLE -16 
RELATIONSHIP OF MPV, PDW AND OTHER PARAMETERS 
 The relationship between MPV, PDW and other parameters are 
statistically significant. 
 
PDW MPV 
Mean Mean 
AGE_GROUP 
20-40 11.73 9.37 
41-60 12.20 9.52 
61-80 12.69 9.81 
ABOVE 80 14.70 10.35 
SEX 
Male 12.11 9.55 
Female 12.61 9.62 
SMOKING 
YES 12.54 9.79 
NO 11.95 9.33 
DIABETES 
YES 13.17 10.08 
NO 11.73 9.28 
HYPERTENSION 
YES 12.73 9.90 
NO 11.86 9.30 
DEATH 
YES 16.30 11.58 
NO 12.85 10.18 
 
  
72 
 
TABLE 17 
RELATIONSHIP BETWEEN AGE WITH MPV, PDW 
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13.17
11.73
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9
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12.73
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11.4
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HTN PDW
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9.3
9
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 CASE MI CONTROL P VALUE 
AGE 52.98±15.00 49.03±10.36 0.167 
MALE  NO 45(69%) 25(71%) 0.819 
CORONARY RISK FACTORS 
DM 36 (55%) 27(77%) 0.032* 
HTN 30(46%) 2469%) 0.032 
SMOKING 25(38%) 22(63%) 0.02* 
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DISCUSSION 
 Myocardial infarction is a major cause of morbidity and mortality 
in developed countries and is major problem in developing countries like 
India. The projection of large increase in Ischemic heart disease  
throughout worldwide, IHD is  likely become most common of death 
worldwide by 2020.( Harrison’s 2015)43.Endogenous and exogenous risk  
factors like smoking, dyslipedemia, diabetes mellitus and systemic 
hypertension significantly increase the individual risk for myocardial 
infarction. However they only explain a part of the cases and there may 
be other relevant risk factors which need to be identified. Large platelets 
are more reactive, produce more thrombotic factors (Martin et al,1983)44 
and aggregate more easily (Haver et al,1981)45               
            Endler et al (2002)46 stated that mean platelet volume (MPV) is an 
independent risk factor for myocardial infarction. Similar observation 
were made by Martin et al (1983),Cameron et al(1983)47.But all these are 
studies conducted in the west with healthy western people serving as 
controls. so in this study an attempt was made to find out if any  
association existed between the platelet size and the occurrence of 
myocardial infarction among Indian population as reports are scanty. 
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 In the study, the ages of the cases ranged from 20 to 80 years. The 
mean was 52.98 ±15 years. The maximum number of cases i.e.,25 cases  
fell in the age group 40-60 years. This comes to 38.5% of the total cases. 
With male predominant 69.2 % among total cases. This pattern 
corresponds to pattern reported in India, which is as follows. Coronary  
artery disease appears a decade earlier compared with the age incidence  
in developed countries and the peak period is attained between 51-60 
years.(Park K.) 
 In the present study the relationship between age and MPV was 
Statistically significant as per Funiak et al (1994) found that MPV was 
significantly increased in patients of advanced age and it was statistically 
significant. But Bancroft et al (2000) stated that MPV decreases with  
age. But our study confirm with observation made by Funiak et al(1994). 
 Among 65 cases, 45 males (69.2%) and 20 females (30.8%).Before 
menopause, women have a lower age adjusted incidence and mortality for 
coronary heart disease than men. Gender specific incidence rates 
converge after menopause, suggesting a major role for oestrogen in 
delaying progression of atherosclerosis. Much of this effect results from 
beneficial action of oestrogen on lipid fractions. Estrogen reduces LDL-C 
by 10-15 %while increasing HDL-C. 
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 In the present study MPV was independent of genders. This is in  
parallel with the observation made by Bancroft et al (2000).   
 Among 65 cases, 40 smokers (75.5%) and among 35 controls 13 
smokers (24.5%).Although this shows an increased prevalence of  
smoking habit among  cases than controls ,it was  statistically significant. 
It has been calculated that in countries where smoking has been a wide 
spread habit, it is responsible for 25% of coronary heart disease death 
under 65 years of age(WHO).A uniquely human habit, smoking has been 
identified as a major coronary risk factor.  
 Although the MPV was higher among smokers compared to 
controls, the relationship was statistically significant. Tschope et al  
(1989)48 and (Kario et al (1982) in separate studies found smokers to have 
an increased MPV. But Kishk et al (1985)49 observed no relation between 
smoking and MPV. Our finding runs in parallel with that of Tschope et 
al(1985). 
 Among the myocardial infarction patients 35 had systemic 
hypertension (76.1%) .In study conducted by Gupta et al (2001) on 
myocardial infarction, the prevalence of systemic hypertension in 
myocardial infarction patients was found to be 32.6%. 
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 In the study shows statistically significant relationship was 
observed between systemic hypertension and MPV, PDW. Osuna et al 
(1998) observed a higher MPV in those with systemic hypertension. In 
contrast, Bath et al (1996) observed no relationship between MPV and 
systemic hypertension. 
 Among myocardial infarction patients diabetes  29(78.4%).This is 
similar to the prevalence of diabetes mellitus in myocardial infarction  
patients in the study by Gupta et al (2001),which was 21%. 
 The MPV, PDW  in patients with diabetes mellitus significantly 
larger from those without diabetes. Sharpe et al (1993)50 stated that MPV 
and PDW was significantly increased in diabetic subjects compared with 
non diabetics. They stated that since the platelet size is a determinant of 
platelet function, with larger platelets being more reactive per unit 
volume, the platelets might play a part in the micro and macro vascular 
complications of diabetes mellitus. Osuna et al (1998) also observed a 
higher MPV with diabetes mellitus. The fact that in our study, 
observation runs parallel to that in Osuna et al (1998). 
 In the present study mean platelet count of the cases was 
4.98±0.23lakhs/mm³ and that of the controls was 1.29±0.42 
Lakhs/mm³.Although the mean platelet count among the cases was more  
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compared to the controls it was statistically significant. Senaran et al 
(2001)51stated that patients with acute myocardial infarction had  
increased platelet counts. Their observation was that in patients with  
myocardial infarction there were increased thrombopoeitin levels.  
 Increased thrombopoeitin levels may increase both platelet counts 
and  platelet size, resulting in haemoststically more active platelets, which  
may contribute to the development and progression of coronary artery  
disease. However the observation by Senaran et al(2001) was in contrast  
to that of Cameron et al(1983) as they noticed that patients with acute  
myocardial infarction had a reduced platelet count compared to the  
controls. They suggested that reduced platelet count may be due to  
consumption of platelet at the thrombus site. But in our study, there was 
significant difference in the platelet counts between the case and the 
control groups. 
 There was significant relationship between platelet count and 
MPV, PDW in our study. There are few studies regarding this aspect. 
Senaran et al(2001) observed both an increased platelet count and MPV 
in patients with myocardial infarction as stated above. But Cameron et al 
(1983) observed a reduced platelet count and higher MPV in patient with 
myocardial infarction. They stated that the reduced platelet count may be 
due to the consumption of platelet at the thrombus site as stated above. 
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 The observation in our study runs in parallel with the finding of 
Senaran et al. 
 The MPV of the cases ranged from 8.4 to 12 femtolitres with a 
mean of 10.2 ± 1.1femtolitres.The MPV of the controls ranged from 7 to 
10.60 femtolitres with mean of 8.29±0.9 femtolitres. The difference 
between the two was statistically significant. 
 Previous studies on MPV and myocardial  infarction have given 
different observations. 
 Halbmayer et al(1995) stated that MPV did not differ significantly 
between patients and controls in their study. In contrast to this Cameron 
et al (1983) found an increased mean platelet volume among those with 
acute myocardial infarction compared to controls.  
 Similar finding was observed by Martin et al(1983) in their study. 
Large platelets are denser, they produce more thromboxane A2 per unit 
volume of platelet cytoplasm. Large platelets aggregate more rapidly 
upon collagen challenge, release more serotonin and other granule 
contents and express more receptors per unit area(pizzuli et al,1998).So 
an increased MPV, as an indicator of larger, more reactive platelets, may 
represent a risk factor for myocardial infarction(Endler et al,2002) 
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 One question is that, does the increase in platelet volume occur 
before the event of myocardial infarction or does it occur as a response to 
the platelet consumption in myocardial infarction. Martin et al (1983) 
who did  a study on mean platelet volume in acute myocardial infarction 
measured platelet volume within 12 hours of admission to hospital and 
then later at 6 weeks. They stated that mean platelet volume was 
increased before myocardial infarction occurred for the following 
reasons. They said that increase in volume seen within the first 12 hours 
of admission suggested that the increase was present before infarction, as 
the life span of the platelet is about 8 days. More than 90% of the platelet 
population whose distribution was measured after myocardial infarction 
were circulating before the vascular occlusion occurred. They also 
observed that the increase in MPV persisted six weeks after discharge 
from hospital, when infarct would have been largely healed. This also 
supported the view that platelet volume was chronically large in the 
infarct group. 
 Further proof that the increase in mean platelet volume occurs 
before acute myocardial infarction is got from the study conducted by 
Endler et al (2002).They evaluated mean platelet volume in patients 
presenting with acute myocardial infarction and in patients with a history 
of previous myocardial infarction which had occurred upto 40 years 
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before the study. They compared it with those without myocardial 
infarction. They found that the MPV was significantly raised in those 
with acute MI and in those with history of previous myocardial infarction 
when compared to those without myocardial infarction. They also 
observed that there was no significant difference in the MPV between 
those with acute myocardial infarction and those with history of previous 
myocardial infarction. This showed that the time interval between the 
occurrence of MI and the estimation of MPV did not influence the value 
of MPV. This further adds to the proof that raised MPV  precedes the 
occurrence of MI. 
            O’Malley et al (1995) conducted a similar study of MPV 
estimation in stroke patients. They estimated MPV in stroke patients 
within 48 hours of admission and also at 6 months later and compared it 
with controls. They found that MPV was significantly raised in stroke 
patients compared to controls. They suggested that the changes in MPV  
might have preceded the vascular event and is unlikely to be due to 
platelet consumption at the infarct site. They said that since the average 
life span of the platelets is about 8 days, elevated MPV seen within the  
first 48 hours after stroke represented platelet released before infarction. 
 Further it was unlikely that platelet consumption due to localized 
thrombosis would affect peripheral venous estimation of platelet 
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variables. They further stated that since there was no difference in MPV 
between large cortical strokes and small lacunar infarcts, it was unlikely 
that platelet consumption at the thrombus site would affect the peripheral 
venous estimation of platelet variables. They also added that, the fact that 
the observed increase in MPV had remained unchanged in post stroke  
survivors was further evidence that changes in MPV were likely to have 
preceded the acute event.     
 Although the highest MPV of 13.8 femtolitres, PDW 16.1 ,platelet 
count4, 27,000 was observed in those with least ejection fraction i.e ≤ 
45%, there was statistically significant. Hendra et al (1988) stated that all 
patients with severe cardiac failure had larger platelet volume than 
patients with mild or no failure. Osuna et al (1998) also observed that an 
increased platelet volume was related to higher risk of cardiac failure. 
 But our study showed only significant higher platelet volumes in 
those with left ventricular dysfunction. 
 There was no significant difference in MPV among the group that 
survived without complication and the rest. The 4 patients who died did 
not have statistically significant MPV but had higher PDW level ranged 
18 femtolitres. 
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 According to Hendra J et al (1988)52,Osuna et al(1998) and Martin 
et al(1991) ,the increase in  MPV  appear to provide prognostic 
information during the period of study. They observed that the MPV 
correlate with more established factors determining prognosis after 
infarction such as the size of the infarct. Their observation were in 
contrast to the observation by Cameron et al(1983) 
 According to Assiri et al(2012) 53stated that platelet volume 
parameters mainly MPV and PDW are ,available and inexpensive 
markers ,detected significantly raised in patients admitted with acute 
coronary syndrome. From these observation, they suggested to use 
platelet parameters used to screen patients presenting to emergency room 
with chest pain suspected to have acute coronary syndrome. 
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LIMITATIONS 
 A multi centric study with a larger sample size and longer follow 
up is essential to assess the predictive power of these prognostication 
tools in a more comprehensive manner. 
 
 AREAS OF FURTHER WORK 
1. MPV studies in other thrombotic episodes 
2. Follow up study of MPV after the onset of clinical events and 
finding out association between MPV and platelet count by apply 
the log probability formula. 
3. Studies to find out the physiological mechanism which regulates 
MPV within megakaryocyte. 
4. Invitro studies on factors contributing for thyromegaly in order to 
introduce interventional measures.  
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CONCLUSION 
 MPV was significantly elevated in patients with acute myocardial 
infarction (10.2 ± 1.1femtolitres) when compared with controls8 
(29±0.9 femtolitres). 
 MPV in patients with acute myocardial infarction was found to be 
elevated with advancing age, smoking, diabetes mellitus and systemic 
hypertension. 
 Aspirin was not found to have any significant association with MPV 
 Observed correlation between elevated platelet count and MPV 
 Observed correlation between MPV and short term outcome  after 
myocardial infarction. 
 The study “The platelet count and mean platelet volume and 
platelet distribution width in myocardial infarction “was done to assess 
the relationship between mean platelet volume (MPV) and the occurrence 
of acute myocardial infarction and to find out its association with the risk 
factors and short term prognosis after myocardial infarction With rigid 
criteria 65 patients were selected carefully and were evaluated on social, 
clinical and laboratory aspects after institutional  ethical clearance with an 
informed consent.35 subjects were taken as controls. The data were 
entered in Microsoft Excel spread sheet and analysed statistically. 
 There were 45 males and 20 females in patient group. There were  
25 males and 10 females in control group. The mean age of the patient 
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group was 52.98±15 and that of the control group 49.03±10.36 (p value 
0.167 –not statistically significant) .The prevalence of smoking systemic 
hypertension, and diabetes mellitus were noticed in both group with  
statistical significance. The mean platelet count of the cases was 
4.98±0.23lakhs/mm³ and that of the controls was 1.29±0.42 Lakhs/mm³ 
(p value 0.050 statistically significant). The MPV of the cases ranged 
from 8.4 to 12 femtolitres with a mean of 10.2 ± 1.1femtolitres.The MPV 
of the controls ranged from 7 to 10.60 femtolitres with mean of 8.29±0.9 
femtolitres. The difference between the two was statistically significant.(p 
value 0.001 significant). 
 There was significantly relationship between age, sex, smoking, 
diabetes mellitus and systemic hypertension platelet count, MPV, 
PDW.MPV was found to be independent of aspirin intake. There was 
correlation observed between MPV and short term prognosis like left  
ventricular dysfunction and death.  
 According to Assiri et al (2012) stated that platelet volume 
parameters mainly MPV and PDW are available and inexpensive 
markers, detected significantly raised in patients admitted with acute 
coronary syndrome. From these observation, they suggested to use 
platelet parameters used to screen patients presenting to emergency room 
with chest pain suspected to have acute coronary syndrome. 
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PROFORMA 
Platelet count and Mean platelet volume and platelet distribution 
Width in Acute coronary syndrome 
 
Name          : 
 
Age/Sex :  
 
Socioeconomic status: 
 
Marital status: 
 
Occupation: 
 
 HISTORY OF PRESENTING ILLNESS 
 
1.chest pain  
 
2.breathlessness 
 
3.cough 
 
4.palpitation 
 
5.sweating 
 
6.syncope 
 
 PAST HISTORY 
 
1.Hypertension 
 
2.Dyslipidemia 
 
3.Acute  or chronic renal disease 
 
4.Chronic lung disease 
 
5.Diabetes Mellitus 
6.Anemia 
 
7.Drug or alcohol abuse 
PERSONEL HISTORY 
 
 
 Smoking 
 
Alcohol 
 
VITALS 
  
Pulse rate: 
 
Respiratory rate: 
 
Blood pressure: 
 
Duration of stay : 
 
 
General examination  
 
 
 
 
Systemic examination 
 
CVS:     RS:    P/A:  
 CNS: 
 
INVESTIGATIONS : 
 
BLOOD PLATELET COUNT  
 
MEAN  PLATELET VOLUME 
 
PLATELET DISTRIBUTION WIDTH 
 
ECHO                           COMPLICATION           DEATH 
 
                                     
 
 
 
  
ABBREVIATIONS AND ACRONOMYS 
 
ADP   - Adenosine diphosphate 
BP   - Blood pressure 
CAD   - Coronary Artery Disease 
MI                          - Myocardial infarction 
MPV                      - Mean platelet Volume 
NO   - Nitric Oxide 
PGI2   - Prostacyclin 
vWF   - von Willebrand factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
                                 INFORMATION SHEET 
  
We are conducting a study on “A STUDY ON PLATELET 
COUNT AND THEIR INDICES –MEAN PLATELET VOLUME 
AND PLATELET DISTRIBUTION WIDTH AND THEIR 
PROGNOSTIC SIGNIFICANCE  IN ACUTE CORONARY 
SYNDROME IN TERTIARY CARE  HOSPITAL”  among patients 
attending Rajiv Gandhi Government General Hospital, Chennai and for 
that your specimen may be valuable to us. 
 
The purpose of this study is to assess the“A STUDY ON 
PLATELET COUNT AND THEIR INDICES –MEAN PLATELET 
VOLUME AND PLATELET DISTRIBUTION WIDTH AND 
THEIR PROGNOSTIC SIGNIFICANCE  IN ACUTE CORONARY 
SYNDROME IN TERTIARY CARE  HOSPITAL”   and We are 
selecting certain cases and if you are found eligible physical examination 
done. 5ml blood will be collected and 2ml of urine will be collected. You 
will also undergo echocardiogram, electrocardiogram, chest x-ray. These 
tests and special studies do not affect your final report or management. 
 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
         Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
         The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
 
Signature of Investigator                              signature of participant 
Date: 
Place: 
 

                              PATIENTS CONSENT FORM 
 
Study title 
 
: A STUDY ON PLATELET COUNT AND 
THEIR INDICES –MEAN PLATELET 
VOLUME AND PLATELET DISTRIBUTION 
WIDTH AND THEIR PROGNOSTIC 
SIGNIFICANCE  IN ACUTE CORONARY 
SYNDROME IN TERTIARY CARE  
HOSPITAL 
 
 
Study Centre 
 
: 
 
Rajiv Gandhi Government General Hospital, 
Chennai. 
   
Name 
 
:  
Age/Sex 
 
:  
Identification 
Number 
 
:  
                                    Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained 
to me in my own language 
 ❏ 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. 
 ❏ 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be conducted 
in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required ❏ 

under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and 
to immediately inform the study staff if I suffer from any deterioration 
in my health or wellbeing or any unexpected or unusual symptoms. 
 ❏ 
I hereby consent to participate in this study. 
 ❏ 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological and biochemical tests. ❏ 
 
 
Signature/thumb impression 
 
 
Patient’s Name and Address:                                       
 
 
Signature of Investigator 
Study Investigator’s Name: 
Dr. M.ANITHA   
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ABBREVIATIONS IN MASTER CHART 
 
SEX      1-Male, 2-Female 
SYS.H.T   - systemic Hypertension 
DIA.MELL   - Diabetes mellitus 
ON.ASP   - On aspirin 
PLAT.COUNT  - platelet count 
MPV    - Mean platelet count 
PDW    - platelet distribution Width 
EJEC.FRA   - Ejection Fraction 
For these parameters 1 - YES,2-NO 
